Head, Division of Cell-Based Therapeutic Products National Institute of Health Sciences, Kanagawa, Japan
Dr. Yoji Sato is the Head of Division of Cell-Based Therapeutic Products, Japan National Institute of Health Sciences. As a graduate student at the University of Tokyo and as a postdoc at the University of Cincinnati, he conducted researches on cardiovascular pharmacology, and succeeded in establishing a variety of transgenic mouse models to elucidate mechanisms of cardiac excitation-contraction coupling and heart failure. Dr. Sato’s current research area is in the field of regulatory science for the quality and safety of cell therapy products (CTPs). He is currently leading a public-private partnership initiative (MEASURE Project) in Japan for validation of test methods for tumorigenicity assessment of CTPs, in collaboration with the Committee for Non-Clinical Safety Evaluation of Pluripotent Stem Cell-Derived Therapeutic Products, Forum for Innovative Regenerative Medicine (FIRM-CoNCEPT) and the Cell Therapy-TRAcking, Circulation and Safety Committee, the Health and Environmental Sciences Institute (HESI CT-TRACS). He is also serving as the Vice Chair of the Database Committee, the Japanese Society for Regenerative Medicine, which provides the National Regenerative Medicine Database (NRMD), a nation-wide patient registry system for clinical researches and post-marketing studies on CTPs, and as a topic leader of ICH-Q5A(R2) as well as a member of Technical Committees, Panel on Science and Technology, Health Science Council, the Japan Ministry of Health Labour and Welfare.